Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337754 | 0.90 | L3MBTL1 (0.45) | MAP2K1L3MBTL1MAP2K2ABCB11NQO2 | |
| SCHEMBL4321814 | 0.89 | MAP2K1 (0.49) | MAP2K1L3MBTL1MAP2K2ABCB11NQO2 | |
| SCHEMBL4326005 | 0.81 | MAP2K1 (0.59) | MAP2K1MAP2K2ABCB11NQO2KMT2A | |
| SCHEMBL4334335 | 0.79 | MAP2K1 (0.53) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL4324520 | 0.79 | MAP2K1 (0.46) | MAP2K1L3MBTL1MAP2K2ABCB11NQO2 | |
| SCHEMBL1344228 | 0.77 | MAP2K1 (0.45) | MAP2K1L3MBTL1MAP2K2ABCB11NQO2 | |
| SCHEMBL3047450 | 0.77 | MAP2K1 (0.57) | MAP2K1L3MBTL1MAP2K2KMT2A | |
| SCHEMBL4332409 | 0.75 | MAP2K1 (0.37) | MAP2K1L3MBTL1MAP2K2ABCB11NQO2 | |
| SCHEMBL29413374 | 0.74 | MAP2K1 (0.55) | MAP2K1L3MBTL1MAP2K2TP53MAPT | |
| SCHEMBL1488056 | 0.74 | MAP2K1 (0.55) | MAP2K1L3MBTL1MAP2K2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1689406-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689406-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 77/4885L3MBTL1 1588/4885MAP2K2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.